Gastroenterology

Arthritis drug could let coeliac patients eat gluten

Tofacitinib, a Janus kinase inhibitor approved to treat rheumatoid arthritis and bowel diseases, may allow patients with celiac disease to eat gluten without experiencing intestinal and extraintestinal symptoms. A case report ...

Medications

Recommendations provided for treatment of ulcerative colitis

(HealthDay)—In a new clinical guideline from the American Gastroenterological Association, recently published in Gastroenterology, treatment recommendations are presented for patients with moderate-to-severe ulcerative ...

Diabetes

T2DM remission rates higher with RYGB versus sleeve gastrectomy

(HealthDay)—Most patients with type 2 diabetes mellitus (T2DM) undergoing bariatric surgery experience T2DM remission during five years of follow-up, but outcomes are superior with Roux-en-Y gastric bypass (RYGB) compared ...

Arthritis & Rheumatism

MRI-identified damage tied to patient-reported RA function

(HealthDay)—There is a consistent association between magnetic resonance imaging (MRI) findings of damage in the wrist and hand and self-reported loss of function in patients with established rheumatoid arthritis (RA) in ...

Oncology & Cancer

Gilteritinib superior in relapsed, refractory FLT3-mutated AML

(HealthDay)—For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer ...

Inflammatory disorders

The diet-microbiome connection in inflammatory bowel disease

Much remains mysterious about the factors influencing human inflammatory bowel disease (IBD), but one aspect that has emerged as a key contributor is the gut microbiome, the collection of microorganisms dwelling in the intestines.

Medications

Rituximab noninferior to cyclosporine in membranous nephropathy

(HealthDay)—In patients with membranous nephropathy at high risk for progressive disease, rituximab is noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and is superior in ...

page 2 from 16